DR. SUJATHA NALLAPAREDDY MD NPI 1164578779

NPI Information

  • NPI: 1164578779
  • Provider Name: DR. SUJATHA NALLAPAREDDY, MD
  • Classification: Internal Medicine - 207RH0003X
  • Specialization: Hematology & Oncology
  • Entity Type: Individual
  • PECOS Registration: Yes
  • Address: 1700 S POTOMAC ST
    AURORA, CO
    ZIP 80012
  • Phone: (303) 418-7600

Map and Directions

Get Directions

NPI Details

DR. Sujatha Nallapareddy, MD is a hematology and oncology internal medicine in Aurora, CO with 27 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Sujatha Nallapareddy, MD NPI is 1164578779. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

1700 S POTOMAC ST
AURORA, CO
ZIP 80012-405
Phone: (303) 418-7600
Fax: (303) 750-3137

The NPI 1164578779 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

  • Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
  • Injection, fosaprepitant, 1 mg (HCPCS:J1453)
  • Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
  • Injection, pembrolizumab, 1 mg (HCPCS:J9271)
  • Injection, iron sucrose, 1 mg (HCPCS:J1756)
  • Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
  • Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
  • Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
  • Injection, paclitaxel, 1 mg (HCPCS:J9267)
  • Injection, aprepitant, 1 mg (HCPCS:J0185)
  • Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
  • Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
  • Injection, denosumab, 1 mg (HCPCS:J0897)
  • Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
  • Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
  • Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
  • Insertion of needle into vein for collection of blood sample (HCPCS:36415)
  • Injection, fluorouracil, 500 mg (HCPCS:J9190)
  • Blood test, comprehensive group of blood chemicals (HCPCS:80053)
  • Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
  • Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
  • Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
  • Injection of additional new drug or substance into vein (HCPCS:96375)
  • Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
  • Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
  • Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
  • Injection of drug or substance under skin or into muscle (HCPCS:96372)
  • Ferritin (blood protein) level (HCPCS:82728)
  • Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
  • Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
  • Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
  • Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
  • Injection, carboplatin, 50 mg (HCPCS:J9045)
  • Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
  • Iron level (HCPCS:83540)
  • Iron binding capacity (HCPCS:83550)
  • Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
  • Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
  • Urinalysis, manual test (HCPCS:81002)
  • Injection, zoledronic acid, 1 mg (HCPCS:J3489)
  • Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
  • Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
  • New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
  • Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
  • Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
  • Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
  • Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
  • Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
  • Unclassified drugs (HCPCS:J3490)
  • Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
  • Gammaglobulin (immune system protein) measurement (HCPCS:82784)
  • Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
  • Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
  • Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
  • Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
  • Magnesium level (HCPCS:83735)
  • Lactate dehydrogenase (enzyme) level (HCPCS:83615)
  • Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
  • Reticulated (young) platelet measurement (HCPCS:85055)
  • Measurement of immunoglobulin light chains (HCPCS:83521)
  • Application of on-body injector for under skin injection (HCPCS:96377)
  • Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
  • Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
  • Drawing of blood for a medical problem (HCPCS:99195)
  • Complete blood cell count (red cells, white blood cell, platelets), automated test (HCPCS:85027)
  • Phosphate level (HCPCS:84100)
  • Protein measurement, serum (HCPCS:84165)
  • Refilling and maintenance of portable pump (HCPCS:96521)
  • New patient office or other outpatient visit, 30-44 minutes (HCPCS:99203)
  • Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
  • Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
  • Infusion into a vein for hydration, each additional hour (HCPCS:96361)
  • Immunologic analysis technique on serum (immunofixation) (HCPCS:86334)
  • Collection of blood sample from implanted device (HCPCS:36591)
  • Irrigation of implanted venous access drug delivery device (HCPCS:96523)
  • Declotting of central venous tube (HCPCS:36593)
  • New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
  • Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
  • Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
  • Total protein level, blood (HCPCS:84155)
  • Injection of drug or substance into vein (HCPCS:96374)
  • New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)

The enumeration date for this NPI number is 1/26/2007 and was last updated on 2/17/2025.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

No. Taxonomy Code Taxonomy Clasification Taxonomy Specialization License Number License State Primary
1207RH0003XInternal MedicineHematology & OncologyDR.0046114COLORADOYes

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.

No. Other Provider Identifier Other Provider Identifier Type Other Provider Identifier State Other Provider Identifier Issuer
131902871MEDICAIDCOLORADO

What is NPI?

NPI stands for National Provider Identifier. The NPI is a 10-digit identification number that is completely unique. The NPI number by itself does not contain any identifiable information such as a provider’s speciality or location. The NPI is assigned to individuals or organizacions for their lifespan and it is independent of key provider information type updates like a change of practices, location or speciality.

This page was last updated on: 11/21/2025

NPI Synchronization or Removal

All materials and services on this site are provided on an "as is" and "as available" basis without warranty of any kind. The NPI record is maintained by the National Plan & Provider Enumeration System (NPPES) and anyone may request this information and other NPPES health care provider data from HHS under The Freedom of Information Act (FOIA), Title 5 of the United States Code, section 552. To update the NPI records please contact the NPPES.